These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 28188841)

  • 1. Bayesian clinical trial design using Markov models with applications to autoimmune disease.
    Eggleston BS; Ibrahim JG; Catellier D
    Contemp Clin Trials; 2017 Dec; 63():73-83. PubMed ID: 28188841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
    Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
    BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
    Morita S; Yamamoto H; Sugitani Y
    Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian model selection: analysis of a survival model with a surviving fraction.
    Seltman H; Greenhouse J; Wasserman L
    Stat Med; 2001 Jun; 20(11):1681-91. PubMed ID: 11391695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust meta-analytic-predictive priors in clinical trials with historical control information.
    Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
    Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials.
    Odani M; Fukimbara S; Sato T
    Clin Trials; 2017 Apr; 14(2):192-200. PubMed ID: 28059578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian randomized clinical trials: From fixed to adaptive design.
    Yin G; Lam CK; Shi H
    Contemp Clin Trials; 2017 Aug; 59():77-86. PubMed ID: 28455232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constructing intervals for the intracluster correlation coefficient using Bayesian modelling, and application in cluster randomized trials.
    Turner RM; Omar RZ; Thompson SG
    Stat Med; 2006 May; 25(9):1443-56. PubMed ID: 16220510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empirical Bayes models of Poisson clinical trials and sample size determination.
    Zaslavsky BG
    Pharm Stat; 2010; 9(2):133-41. PubMed ID: 19513984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian methods of analysis for cluster randomized trials with count outcome data.
    Clark AB; Bachmann MO
    Stat Med; 2010 Jan; 29(2):199-209. PubMed ID: 19856321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covariate-adjusted borrowing of historical control data in randomized clinical trials.
    Han B; Zhan J; John Zhong Z; Liu D; Lindborg S
    Pharm Stat; 2017 Jul; 16(4):296-308. PubMed ID: 28560815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome.
    Chen MH; Ibrahim JG; Zeng D; Hu K; Jia C
    Biometrics; 2014 Dec; 70(4):1003-13. PubMed ID: 25041037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inclusion of historical control data may reduce the power of a confirmatory study.
    Cuffe RL
    Stat Med; 2011 May; 30(12):1329-38. PubMed ID: 21432893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
    Jordan P; Brunschwig H; Luedin E
    Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
    Xie F; Ji Y; Tremmel L
    Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified power prior with multiple historical trials for binary endpoints.
    Banbeta A; van Rosmalen J; Dejardin D; Lesaffre E
    Stat Med; 2019 Mar; 38(7):1147-1169. PubMed ID: 30360016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical Bayesian design and analysis for drug and device clinical trials.
    Hobbs BP; Carlin BP
    J Biopharm Stat; 2008; 18(1):54-80. PubMed ID: 18161542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A practical Bayesian adaptive design incorporating data from historical controls.
    Psioda MA; Soukup M; Ibrahim JG
    Stat Med; 2018 Nov; 37(27):4054-4070. PubMed ID: 30033617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for mid-course corrections in clinical trials with survival outcomes.
    Cook TD
    Stat Med; 2003 Nov; 22(22):3431-47. PubMed ID: 14601011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.